Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Cancer statistics in China, 2015
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21338 · Cited by 17,038
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Non-small cell lung cancer: current treatment and future advances
Zappa, C., & Mousa, S. A. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.06.07 · Cited by 1,944
Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?
Feng, R., Zong, Y., Cao, S., & Xu, R. (2019) · Cancer Communications · doi:10.1186/s40880-019-0368-6 · Cited by 1,625
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., Wu, X., Ma, J., Zhou, M., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0928-4 · Cited by 1,457
The Therapeutic Potential of Apigenin
Salehi, B., Venditti, A., Sharifi-Rad, M., Kręgiel, D., Sharifi-Rad, J., Durazzo, A., Lucarini, M., Santini, A., Souto, E. B., Novellino, E., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061305 · Cited by 1,238
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,231
Gide, T. N., Quek, C., Menzies, A. M., Tasker, A. T., Shang, P., Holst, J., Madore, J., Lim, S. Y., Velickovic, R., Wongchenko, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.003 · Cited by 1,047
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Burr, M. L., Sparbier, C. E., Chan, Y.-C., Williamson, J. C., Woods, K., Beavis, P. A., Lam, E. Y. N., Henderson, M. A., Bell, C. C., Stolzenburg, S., et al. (2017) · Nature · doi:10.1038/nature23643 · Cited by 946
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Yuan, M., Huang, L.-L., Chen, J.-H., Wu, J., & Xu, Q. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0099-9 · Cited by 679
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
Bai, L., Zhou, H., Xu, R., Zhao, Y., Chinnaswamy, K., McEachern, D., Chen, J., Yang, C.-Y., Liu, Z., Wang, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.002 · Cited by 652
Self-citationKoyama, S., Akbay, E. A., Li, Y. Y., Aref, A. R., Skoulidis, F., Herter-Sprie, G. S., Buczkowski, K. A., Liu, Y., Awad, M. M., Denning, W. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1439 · Cited by 640
Alspach, E., Lussier, D. M., & Schreiber, R. D. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028480 · Cited by 603
Apigenin in cancer therapy: anti-cancer effects and mechanisms of action
Yan, X., Qi, M., Li, P., Zhan, Y., & Shao, H. (2017) · Cell & Bioscience · doi:10.1186/s13578-017-0179-x · Cited by 545
Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer
Wang, S.-S., Liu, W., Ly, D., Xu, H., Qu, L., & Zhang, L. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-018-0027-x · Cited by 524
Antibacterial Activity of Some Flavonoids and Organic Acids Widely Distributed in Plants
Adamczak, A., Ożarowski, M., & Karpiński, T. M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010109 · Cited by 478
Cheng, Z., Yu, C., Cui, S., Wang, H., Jin, H., Wang, C., Li, B., Qin, M., Yang, C., He, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11162-4 · Cited by 421
The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion
Mojic, M., Takeda, K., & Hayakawa, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010089 · Cited by 334
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma
Chen, N., Fang, W., Lin, Z., Peng, P., Wang, J., Zhan, J., Hong, S., Huang, J., Liu, L., Sheng, J., et al. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2005-z · Cited by 288
Self-citationLiu, C., Zheng, S., Jin, R., Wang, X., Wang, F., Zang, R., Xu, H., Lu, Z., Huang, J., Lei, Y., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.10.027 · Cited by 281
Self-citationLin, A., Wei, T., Meng, H., Luo, P., & Zhang, J. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1062-7 · Cited by 264
MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer
Maeda, T., Hiraki, M., Jin, C., Rajabi, H., Tagde, A., Alam, M., Bouillez, A., Hu, X., Suzuki, Y., Miyo, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1636 · Cited by 250
Menares, E., Gálvez-Cancino, F., Cáceres-Morgado, P., Ghorani, E., López, E., Díaz, X., Saavedra-Almarza, J., Figueroa, D. A., Roa, E., Quezada, S. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12319-x · Cited by 237
Raedler, L. A. (2015) · PubMed · Cited by 193
Flavonoids in Cancer Metastasis
Liskova, A., Koklesova, L., Samec, M., Smejkal, K., Samuel, S. M., Varghese, E., Abotaleb, M., Biringer, K., Kudela, E., Danko, J., et al. (2020) · Cancers · doi:10.3390/cancers12061498 · Cited by 188
Xu, L., Zhang, Y., Tian, K., Chen, X., Zhang, R., Mu, X., Wu, Y., Wang, D., Wang, S., Liu, F., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0929-6 · Cited by 177
Self-citationSynergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer
Herter-Sprie, G. S., Koyama, S., Korideck, H., Hai, J., Deng, J., Li, Y. Y., Buczkowski, K. A., Grant, A. K., Ullas, S., Rhee, K., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87415 · Cited by 161
PAK4 inhibition improves PD-1 blockade immunotherapy
Abril-Rodriguez, G., Torrejon, D. Y., Liu, W., Zaretsky, J. M., Nowicki, T. S., Tsoi, J., Puig-Saus, C., Baselga-Carretero, I., Medina, E., Quist, M. J., et al. (2019) · Nature Cancer · doi:10.1038/s43018-019-0003-0 · Cited by 157
Flavonoids: New Frontier for Immuno-Regulation and Breast Cancer Control
Sudhakaran, M., Sardesai, S. D., & Doseff, A. I. (2019) · Antioxidants · doi:10.3390/antiox8040103 · Cited by 134
Li, Y.-W., Xu, J., Zhu, G., Huang, Z., Lu, Y., Li, X., Wang, N., & Zhang, F. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0124-8 · Cited by 133
Coombs, M. R. P., Harrison, M. E., & Hoskin, D. W. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.06.023 · Cited by 126
Ma, H. S., Poudel, B., Torres, E. R., Sidhom, J.-W., Robinson, T. M., Christmas, B., Scott, B., Cruz, K., Woolman, S., Wall, V. Z., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0061 · Cited by 126
Williams, J. B., Li, S., Higgs, E. F., Cabanov, A., Wang, X., Huang, H., & Gajewski, T. F. (2020) · Nature Communications · doi:10.1038/s41467-020-14290-4 · Cited by 122
Self-citationMUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer
Bouillez, A., Rajabi, H., Jin, C., Samur, M., Tagde, A., Alam, M., Hiraki, M., Maeda, T., Hu, X., Adeegbe, D., et al. (2017) · Oncogene · doi:10.1038/onc.2017.47 · Cited by 120
Oncogenic driver genes and tumor microenvironment determine the type of liver cancer
Wang, G., Wang, Q., Liang, N. N., Xue, H., Yang, T., Chen, X., Qiu, Z., Zeng, C., Sun, T., Yuan, W., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2509-x · Cited by 119
Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer
Halliday, P. R., Blakely, C. M., & Bivona, T. G. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0770-x · Cited by 115
Luo, F., Luo, M., Rong, Q., Zhang, H., Chen, Z., Wang, F., Zhao, H.-Y., & Fu, L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0733-7 · Cited by 113
Trefny, M. P., Kaiser, M., Stanczak, M. A., Herzig, P., Savic, S., Wiese, M. N., Lardinois, D., Laubli, H. P., Uhlenbrock, F., & Zippelius, A. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02558-z · Cited by 92
Koh, J., Kim, H. Y., Lee, Y., Park, I. K., Kang, C. H., Kim, Y. T., Kim, J.-E., Choi, M., Lee, W., Jeon, Y. K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3458 · Cited by 86
Shao, B., Li, C.-W., Lim, S., Sun, L., Lai, Y., Hou, J., Liu, C., Chang, C.-W. M., Qiu, Y., Hsu, J.-M., et al. (2018) · Europe PMC (PubMed Central) · Cited by 82
Lee, J. W., Zhang, Y., Eoh, K. J., Sharma, R., Sanmamed, M. F., Wu, J., Choi, J., Park, H. S., Iwasaki, A., Kaftan, E., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.004 · Cited by 80
Self-citationA bright future for KRAS inhibitors
Bar-Sagi, D., Knelson, E. H., & Sequist, L. V. (2020) · Nature Cancer · doi:10.1038/s43018-019-0016-8 · Cited by 74
Choi, H., Deng, J., Li, S., Silk, T., Dong, L., Brea, E. J., Houghton, S., Redmond, D., Zhong, H., Boiarsky, J., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.066 · Cited by 72
TORRALVO, J., FRIEDLAENDER, A., ACHARD, V., & ADDEO, A. (2019) · Cancer Genomics - Proteomics · doi:10.21873/cgp.20160 · Cited by 71
Li, R.-Z., Fan, X., Duan, F., Jiang, Z., Pan, H., Luo, L., Zhou, Y., Li, Y., Yao, Y., Yao, X., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0733-4 · Cited by 65
Self-citationCouture, R., Mora, N., Bittar, S. A., Najih, M., Touaibia, M., & Martin, L. J. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09481-9 · Cited by 55
Ferino, A., Rapozzi, V., & Xodo, L. E. (2020) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/j.jphotobiol.2019.111672 · Cited by 51
Medina‐Echeverz, J., Hinterberger, M., Testori, M., Geiger, M., Giessel, R., Bathke, B., Kassub, R., Gräbnitz, F., Fiore, G., Wennier, S. T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12998-6 · Cited by 49
Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology
Kasten, B. B., Udayakumar, N., Leavenworth, J. W., Wu, A. M., Lapi, S. E., McConathy, J., Sorace, A. G., Bag, A. K., Markert, J. M., & Warram, J. M. (2019) · Theranostics · doi:10.7150/thno.34415 · Cited by 47
Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma
Galvani, E., Mundra, P. A., Valpione, S., García-Martínez, P. L., Smith, M., Greenall, J., Thakur, R., Helmink, B. A., Andrews, M. C., Boon, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14632-2 · Cited by 46
Schoenhals, J. E., Seyedin, S. N., Anderson, C., Brooks, E. D., Li, Y. R., Younes, A. I. A., Niknam, S., Li, A., Barsoumian, H. B., Cortez, M. A., et al. (2007) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.03.06 · Cited by 45
Wang, W., Mao, L., Lai, H., Wang, Y., Jiang, Z., Li, W., Huang, J., Xie, Y., Xu, C., Liu, P., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105129 · Cited by 40
Self-citationLeung, E. L., Luo, L. X., Li, Y., Liu, Z., Li, L. L., Shi, D. F., Xie, Y., Huang, M., Lu, L. L., Duan, F. G., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32222 · Cited by 39
Self-citationIn situ antitumor vaccination: Targeting the tumor microenvironment
Li, H., Yu, J., Wu, Y., Shao, B., & Wei, X. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29551 · Cited by 35
An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer
von Karstedt, S., & Walczak, H. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0249-4 · Cited by 22
Li, X., Wang, M., & Xiang, R. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0077-2 · Cited by 13
Lim, M. S., Beyer, T., Babayan, A., Bergmann, M. M., Brehme, M., Buyx, A., Czernin, J. G., Egger, G., Elenitoba‐Johnson, K. S. J., Gückel, B., et al. (2019) · Molecular Imaging and Biology · doi:10.1007/s11307-019-01361-2 · Cited by 4
Cited by
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Liu, Z., Xu, X., Liu, H., Zhao, X., Yang, C., & Fu, R. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-023-00456-5 · Cited by 40
“…and its derivative api-genin, and the enhancement of their anti-tumour ability has been associated with the down-regulation of PD-L1 expression [115]; Cilibin overcomes PD-L1-mediated drug resistance in nasopharyngeal carcinoma by down-regulating PD-L1 expression [116]; KYA1797K down-regulates…”
Background
Metadata
- Authors
- Jiang, Z.-B., Wang, W.-J., Xu, C., Xie, Y.-J., Wang, X.-R., Zhang, Y.-Z., Huang, J.-M., Huang, M., Xie, C., Liu, P., Fan, X.-X., Ma, Y.-P., Yan, P.-Y., Liu, L., Yao, X.-J., Wu, Q.-B., & Lai-Han Leung, E.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 515
- Pages
- 36-48
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W3165164686
- Cited by
- 229
- References
- 62
- FWCI
- 16.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.